---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000014"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:33:12.452042+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring

## Summary
- Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.
- Cash, equivalents & marketable securities $249.4M at Dec 31, 2024, funding operations into H2 2026.
- CB-010 ANTLER and CB-011 CaMMouflage Phase 1 clinical data expected in H1 2025.
- CSO Steve Kanner to retire end of June 2025; no replacement planned; functions split among execs.
- CFO Sri Ryali appointed in January 2025.

## SEC filing metadata
- accession: 0001619856-25-000014
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/0001619856-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/crbu-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000014
- JSON: https://secwatch.observer/filing/0001619856-25-000014.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.